



---

## FEP Medical Policy Manual

---

### FEP 2.04.69 Fecal Calprotectin Testing

---

**Effective Policy Date: April 1, 2021**

**Original Policy Date: December 2012**

**Related Policies:**

2.04.26 - Fecal Analysis in the Diagnosis of Intestinal Dysbiosis

---

## Fecal Calprotectin Testing

### Description

#### Description

Calprotectin is a calcium- and zinc-binding protein that is a potential marker of intestinal inflammation. Fecal calprotectin testing is proposed as a noninvasive means to diagnose inflammatory bowel disease (IBD). Other potential uses are to evaluate treatment response for patients with IBD and as a marker of relapse.

#### OBJECTIVE

The objective of this evidence review is to determine whether fecal calprotectin testing improves the net health outcome in individuals with or suspected of having inflammatory bowel disease.

---

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

---

## POLICY STATEMENT

Fecal calprotectin testing may be considered **medically necessary** for the evaluation of patients when the differential diagnosis is inflammatory bowel disease or noninflammatory bowel disease (including irritable bowel syndrome) for whom endoscopy with biopsy is being considered.

Fecal calprotectin testing is considered **investigational** in the management of inflammatory bowel disease, including the management of active inflammatory bowel disease and surveillance for relapse of disease in remission.

## POLICY GUIDELINES

A fecal calprotectin level of less than 50 g/g is suggestive of a low likelihood of inflammatory bowel disease.

## BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

## FDA REGULATORY STATUS

In March 2006, the PhiCal (Genova Diagnostics), an enzyme-linked immunosorbent assay test for measuring concentrations of fecal calprotectin in fecal stool, was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. This test is indicated as an aid in the diagnosis of IBD and to differentiate IBD from IBS, when used with other diagnostic testing and clinical considerations.

The PhiCal, as modified by Quest Diagnostics, is classified as a laboratory-developed test. Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). The modified PhiCal is available under the auspices of CLIA. Laboratories that offer laboratory-developed tests must be licensed by CLIA for high-complexity testing.

In 2014, CalPrest (Eurospital SpA) and, in 2016, CalPrestNG (Eurospital SpA) were cleared for marketing by the FDA through the 510(k) process. According to the FDA summary, CalPrest "is identical" to the PhiCal™ test in that they have the same manufacturer. Compared with CalPrest, the "differences in CalPrest NG include the name of the test on the labels, detection antibody, the use of a Horse-radish peroxidase/TMB conjugate/substrate system, the provided Stop solution, the concentration of calibrators and controls in the kit and the dynamic range of the assay."

The fCAL ELISA Calprotectin Test (Bhlmann Laboratories) received FDA clearance in 2018 for the quantitative measurement of fecal calprotectin in human stool. In 2019, ALPCO received 510(k) clearance from the FDA for its new fecal Calprotectin Chemiluminescence ELISA test.<sup>1</sup> This test exhibits a clinical specificity of 95.1% and provides the "lowest false positive rate of any currently cleared calprotectin test without sacrificing clinical sensitivity."

FDA product code: NXO.

Rapid fecal calprotectin tests that can be used in the home or physician's office are commercially available in Europe and Canada (eg, Calprosmart, Calpro AS; Quantum Blue Calprotectin, Bhlmann Laboratories). Rapid tests have not been approved by the FDA for use in the U.S.

---

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

## RATIONALE

### Summary of Evidence

For individuals who have a suspicion of inflammatory bowel disease (IBD) when endoscopy with biopsy is being considered who receive fecal calprotectin testing to select patients who can forgo endoscopy, the evidence includes prospective and retrospective diagnostic accuracy studies and systematic reviews. Relevant outcomes are test validity, symptoms, change in disease status, quality of life (QOL), hospitalizations, and medication use. Twenty-eight studies in a systematic review evaluated the diagnostic accuracy of fecal calprotectin in patients suspected of having IBD for whom noninflammatory bowel disease, such as irritable bowel syndrome, remains a consideration. Studies varied in the fecal calprotectin protein level cutoff used to indicate the presence of disease but most used a cutoff of 50 µg/g, which is the recommended lower bound. Studies have indicated that, at this threshold, the test has a sensitivity of 93% to 99% for IBD and a negative predictive value of 73% to 100% for intestinal inflammation. Out of 100 cases of suspected IBD, approximately 49 invasive tests would be avoided with 1 case missed. In another more recent meta-analysis involving 19 studies where the majority of studies again used the cutoff of 50 µg/g, investigators determined that out of 100 hypothetical patients, 18 non-disease patients would have a colonoscopy performed and 1 patient with IBD would not be referred for a colonoscopy. Additionally, it was determined that incorporating a fecal calprotectin test into the regular diagnostic work-up would reduce the need for colonoscopy by 66.7%. Therefore, fecal calprotectin can be used to inform a decision of whether to proceed with endoscopy. Clinical input supported that the use of fecal calprotectin testing for individuals with suspected IBD provides a clinically meaningful improvement in net health outcomes by providing clinically valid and clinically useful information to guide clinical decision-making. Specifically, fecal calprotectin testing can inform the decision by using a positive fecal calprotectin result to refer for endoscopy with biopsy or to use negative fecal calprotectin results to exclude IBD and avoid endoscopy with biopsy with acceptably low tradeoffs in missed diagnoses of IBD in those who have false-negative fecal calprotectin results. Input further highlighted that the use of fecal calprotectin is particularly important in pediatric populations, where children may not be able to fully participate as medical historians and may have non-specific and/or atypical symptoms. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have active IBD who receive fecal calprotectin testing to monitor disease activity, the evidence includes a systematic review and a randomized controlled trial (RCT). Relevant outcomes are test validity, symptoms, change in disease status, QOL, hospitalizations, and medication use. RCTs are needed to determine whether guiding treatment based on fecal calprotectin levels can improve disease management. A 2017 RCT included fecal calprotectin as 1 of several indicators of inflammation to test the effect of tight control of IBD on health outcomes. The independent contribution of fecal calprotectin could not be determined from this study design. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

For individuals who have IBD in remission who receive fecal calprotectin testing to predict relapse, the evidence includes a systematic review and an RCT. Relevant outcomes are test validity, symptoms, change in disease status, QOL, hospitalizations, and medication use. One RCT found no significant difference in the rate of relapse in patients whose medication was modified based on fecal calprotectin or standard clinical indicators, however, this RCT had design and conduct limitations that affected the interpretation of its results. Further study in high-quality RCTs is needed to determine whether adding fecal calprotectin to standard clinical practice improves the management of IBD patients in remission. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

## SUPPLEMENTAL INFORMATION

### Practice Guidelines and Position Statements

#### American Gastroenterological Association

In 2018, the American Gastroenterological Association (AGA) published a guideline on functional gastrointestinal symptoms in patients with IBD.<sup>20</sup> The AGA recommends a stepwise approach to rule-out ongoing inflammatory activity in IBD patients that includes fecal calprotectin, endoscopy with biopsy, and imaging. The AGA recommends that in those patients with indeterminate fecal calprotectin levels and mild symptoms, calprotectin monitoring at 3 to 6 month intervals may allow anticipatory management of impending flares.

---

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

However, "the optimal cutoff for biomarkers remains a source of debate" and overtreatment for symptoms that are due to functional pathophysiology rather than inflammation can increase adverse effects with no symptomatic benefit.

A 2019 guideline from the AGA on laboratory evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome (IBS) in adults gave a conditional recommendation based on low quality evidence to use either fecal calprotectin or fecal lactoferrin to screen for IBD. A threshold value of 50 µg/g for fecal calprotectin was recommended to optimize sensitivity for IBD.<sup>21</sup>

## American College of Gastroenterology

In 2018, the American College of Gastroenterology published guidelines on the management of Crohn disease in adults.<sup>22</sup> The College gave a strong recommendation based on a moderate level of evidence that fecal calprotectin is a helpful test that should be considered to differentiate the presence of IBD from IBS. A summary statement without a recommendation indicated that fecal calprotectin measurements may have an adjunctive role in monitoring disease activity.

## National Institute for Health and Care Excellence

The National Institute for Health and Care Excellence (2013; recommendation 1.1 was updated in 2017), published guidance on fecal calprotectin testing for inflammatory diseases of the bowel.<sup>23</sup> The guidance made the following recommendations:

1.1 "Faecal calprotectin testing is recommended as an option to support clinicians with the differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) in adults with recent-onset lower gastrointestinal symptoms for whom specialist assessment is being considered, if:

1. cancer is not suspected, having considered the risk factors (for example, age)....

1.2 Faecal calprotectin testing is recommended as an option to support clinicians with the differential diagnosis of IBD or non-IBD (including IBS) in children with suspected IBD who have been referred for specialist assessment...."

## U.S. Preventive Services Task Force Recommendations

Not applicable.

## Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

---

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

## REFERENCES

1. ALPCO. Now available: 510(k) cleared fecal calprotectin ELISA. October 29, 2019. <https://www.alpco.com/now-available-510k-cleared-fecal-calprotectin-elisa>. Accessed October 26, 2020.
2. Petryszyn P, Staniak A, Wolosińska A, et al. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. *Eur J Gastroenterol Hepatol*. Nov 2019; 31(11): 1306-1312. PMID 31464777
3. Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. *Health Technol Assess*. Nov 2013; 17(55): xv-xix, 1-211. PMID 24286461
4. Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. *Clin Chem Lab Med*. 2008; 46(9): 1275-80. PMID 18597588
5. Schoepfer AM, Trummel M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. *Inflamm Bowel Dis*. Jan 2008; 14(1): 32-9. PMID 17924558
6. Basumani P, Bardhan K, Eyre R, et al. Faecal calprotectin: Rotherham experience (unpublished slide presentation). BSG Away; 2012 June 28.
7. Li XG, Lu YM, Gu F, et al. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome]. *Beijing Da Xue Xue Bao Yi Xue Ban*. Jun 18 2006; 38(3): 310-3. PMID 16778979
8. El-Badry A, Sedrak H, Rashed L. Faecal calprotectin in differentiating between functional and organic bowel diseases. *Arab J Gastroenterol*. May 23 2010; 11(2):70-73.
9. Van de Vijver E, Schreuder AB, Cnossen WR, et al. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. *Arch Dis Child*. Dec 2012; 97(12): 1014-8. PMID 23019289
10. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. *Inflamm Bowel Dis*. Mar 2008; 14(3): 359-66. PMID 18050298
11. Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. *Int J Colorectal Dis*. Oct 2008; 23(10): 985-92. PMID 18629518
12. Henderson P, Casey A, Lawrence SJ, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. *Am J Gastroenterol*. Jun 2012; 107(6): 941-9. PMID 22370604
13. Bonnin Tomas A, Vila Vidal M, Rosell Camps A. [Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease]. *Rev Esp Enferm Dig*. Dec 2007; 99(12): 689-93. PMID 18290691
14. Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. *J Pediatr Gastroenterol Nutr*. Apr 2005; 40(4): 450-5. PMID 15795593
15. Jorgensen LG, Fredholm L, Hyltoft Petersen P, et al. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? *Clin Chem Lab Med*. 2005; 43(4): 403-11. PMID 15899657
16. Mosli MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. *Am J Gastroenterol*. Jun 2015; 110(6): 802-19; quiz 820. PMID 25964225
17. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. *Lancet*. Dec 23 2018; 390(10114): 2779-2789. PMID 29096949
18. Heida A, Park KT, van Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. *Inflamm Bowel Dis*. Jun 2017; 23(6): 894-902. PMID 28511198
19. Lasson A, Ohman L, Stotzer PO, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. *United European Gastroenterol J*. Feb 2015; 3(1): 72-9. PMID 25653861
20. Colombel JF, Shin A, Gibson PR. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. *Clin Gastroenterol Hepatol*. Feb 2019; 17(3): 380-390.e1. PMID 30099108
21. Smalley W, Falck-Ytter C, Carrasco-Labra A, et al. Spotlight: Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). *Gastroenterology*. Sep 2019; 157(3): 858. PMID 31377275
22. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. Apr 2018; 113(4): 481-517. PMID 29610508
23. National Institute for Health and Care Excellence (NICE). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel [DG11]. 2013; <http://guidance.nice.org.uk/DG11>. Accessed October 27, 2020.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

**POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:**

<b>Date</b>	<b>Action</b>	<b>Description</b>
December 2012	New policy	Fecal calprotectin testing is considered not medically necessary in the diagnosis and management of intestinal conditions, including the diagnosis and management of inflammatory bowel disease.
June 2013	Replace policy	Policy updated with new literature. No changes to policy statement. References updated.
June 2014	Replace policy	Policy updated with literature review. No change in policy statement. References 2, 5, 16 and 19 added; others renumbered or removed.
September 2015	Replace policy	Policy updated with literature review; references 2, 8, 15-16, and 21 added. No change in policy statement.
March 2017	Replace policy	Policy reviewed with no policy statement changes.
June 2018	Replace policy	Policy updated with literature review through January 8, 2018; references 4, 9- 10, 12, and 18-19 added; references 17-18 updated; some references removed. Policy statement unchanged except "not medically necessary" corrected to "investigational" due to FDA 510(k) status.
September 2019	Replace policy	Policy updated with literature review through September 7, 2018; reference 15 added. Policy statement revised; fecal calprotectin testing is considered medically for the evaluation of patients when the differential diagnosis is inflammatory bowel disease or irritable bowel syndrome for whom endoscopy with biopsy is being considered.
March 2020	Replace policy	Policy updated with literature review through November 12, 2019; references added. Policy statements unchanged.
March 2020	Replace policy	Policy updated with literature review through October 27, 2020; references added. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.